Technology specialist DelsiTech and life science company Bayer have collaborated to develop a new drug delivery technology for Bayer’s compounds in ophthalmology.
Bayer
The two companies have signed a Collaboration and Technology Licence Agreement for the worldwide application of DelSiTech’s Silica Matrix drug delivery technology platform with a number of Bayer’s compounds.
Whilst Bayer will fund all development and commercialisation costs of the collaborative projects, the agreement entitles DelsiTech to a number of milestone payments triggered by the successful completion of different stages of development.
The agreement will support Bayer’s work on treatment options for a range of different eye diseases. Professor Andreas Busch spoke about the difficulties of drug therapies for ophthalmic diseases saying: “Successful ocular drug delivery is one of the biggest challenges in developing novel drug therapies for ophthalmic diseases.”
“This partnership with Bayer is an exciting development for DelSiTech. It follows an already successful and long-lasting collaboration with Bayer in which our Silica Matrix technology has been evaluated,” said Dr. Lasse Leino, CEO of DelSiTech. “We are very pleased that Bayer has chosen DelSiTech as its technology partner for ophthalmology drug delivery. It illustrates the great potential of biodegradable silica material in demanding drug delivery applications.”